Date: Thursday May 31st, 2018
Time: 16:30-19:00 hrs (doors open at 16:00)
Location: Novio Tech Campus, in the SMB Meet & Greet, building M, Transistorweg 5 Nijmegen (directions)

Change of program!
Unfortunately Gerjan Kemperman from Chemconnection had to cancel for business reasons. Fortunately Ypke van Oosterhout from Xenikos is willing to inform us on the next steps after securing an investment of 30 million U.S. dollars to advance the development of Xenikos’ lead compound: T-Guard. Xenikos B.V. is a clinical-stage biopharmaceutical company, developing innovative new immunotherapies, based on conjugated antibodies, designed to improve patient health and quality of life. Currently they are developing a novel therapy for treating acute graft-versus-host disease (aGVHD).

Floris van Delft will focus on “Antibody-Drug Conjugates with Improved Therapeutic Index Based on GlycoConnect™ and HydraSpace™ Technologies”.Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of their best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs their vision is to become the preferred partner in the development of these complex biological therapeutics and realize their ambition – connect to cure.

Presentations are in English and the entrance is free. We welcome new guests, so please feel free to pass on this invitation to relevant people in your network!

We are looking forward to meeting you on May 31st!

The monthly meetings Science Meets Business aim to connect people and exchange knowledge in the world of science and business.